AUTHORS
Selina Luger, MD, FRCPC, Li Chen2, Keith W. Pratz, MD3, Sanam Loghavi, MD4, Alexander E. Perl, MD5, Jessica Kaplan Altman, MD6, Robert Redner, MD7, Amir T. Fathi, MD8, Ayman Qasrawi, MD9, Adrienne Briggs, MD10, Deepa Jeyakumar, MD11, James Foran, FRCPC12, Ellin Berman, MD13, Jonathan Kolitz, MD14, Lindsay Wilde, MD15, Tim Wassenaar, MD, MS16, Vamsi Kota, MD17, Olatoyosi Odenike, MD18, Mithun Shah, MD, PhD19, Emily Curran, MD20, Ashwin Kishtagari, MBBS, MSCI21, Kelly Ross, MD22, Zhuoxin Sun23, Mark R. Litzow, MD24
AFFILIATIONS
1 Perelman School of Medicine, Philadelphia, Pennsylvania, United States
2 DFCI, Boston, United States
3 Perelman School of Medicine, Philadelphia, United States
4 MDACC, Houston, United States
5 University of Pennsylvania, Philadelphia, United States
6 Northwestern, Chicago, United States
7 University of Pittsburgh, Pittsburgh, United States
8 Mass General Hospital, Boston, United States
9 University of Kentucky, Lexington, United States
10 Honor Health, Scottsdale, United States
11 UC Irvine, Irvine, United States
12 Mayo Jacksonville, Jacksonville, United States
13 MSKCC, New York, United States
14 Northwell Cancer Center, Lake Success, United States
15 Thomas Jefferson University, Philadelphia, United States
16 ProHealth Care, Woheaka, United States
17 Georgia Cancer Center, Augusta, United States
18 University of Chicago, Chicago, United States
19 Mayo, Rochester, United States
20 University of Cincinnati, Cincinnati, United States
21 Vanderbilt University, Franklin, United States
22 West Virginia University, Morgantown, United States
23 DFCI, Boston, United States
24 Mayo, Rochester, United States
ABSTRACT
Background
PrECOG PrE0905(PrE0905) (NCT# 03836209) was an open-label, randomized, phase II trial that compared gilteritinib versus midostaurin combined with intensive chemotherapy in newly diagnosed (ND) FLT3-mutated AML. A higher composite complete remission (CRc) rate was observed with gilteritinib but not improvement in the primary endpoint of post-induction FLT3 mutation-negative CRc. . With longer followup we now report PrE0905 survival outcomes.
Methods
Adults aged 18–70 years with ND FLT3-mutated AML were randomized 1:1 to receive daunorubicin 90 mg/m² on days 1–3 and cytarabine 100 mg/m² continuous infusion on days 1–7 combined with either gilteritinib 120 mg daily or midostaurin 50 mg twice daily on days 8–21 during induction and high dose cytarabine consolidation. Patients could proceed to allogeneic hematopoietic cell transplantation (HCT) at investigator discretion. Efficacy analyses were performed in all eligible treated patients. Event-free survival (EFS) was defined as survival without induction failure, relapse following CRc, or death following CRc. Overall survival (OS) was defined as time from randomization until death from any cause. Survival distributions were estimated using the Kaplan–Meier method and compared using two-sided log-rank tests stratified by FLT3 mutation category and NPM1 mutation status. Hazard ratios and 95% confidence intervals were estimated using treatment-only Cox proportional hazards models stratified by the same factors. Sensitivity analyses censored follow-up at the start of HCT. No adjustment for multiplicity was applied, all reported p-values are nominal.
Results
From November 2019 through November 2022, 177 eligible treated patients were enrolled (gilteritinib = 90; midostaurin = 87). Median age was 54, with 27.7% >60 years of age. FLT3-ITD was present in 79.1% and NPM1 mutations in 54.8%. Previously reported response outcomes demonstrated higher CRc rates with gilteritinib versus midostaurin (85.6% vs 72.4%, p=0.042), while post-induction FLT3 mutation-negative CRc rates were similar (40.0% vs 47.1%, p=0.366). Among patients with persistent FLT3 mutation positivity after induction who were evaluable following consolidation cycle 1, conversion to FLT3 mutation negativity occurred in 15/18 (83.3%) patients receiving gilteritinib and 4/9 (44.4%) patients receiving midostaurin (p=0.072).Thirty and sixty day mortality rates for gilteritinib vs midostaurin were 1.1 % vs 1.1% and 2.2% vs. 3.4% respectively) Sixty-six percent of patients receiving gilteritinib compared with 46% receiving midostaurin proceeded to HCT in first remission.
At data cutoff on June 29, 2026, with an estimated median follow-up of 49.5 months, 93 EFS events had occurred (41 with gilteritinib, 52 with midostaurin). Among CRc achievers, 19.7% gilteritinib vs 31.7% midostaurin relapsed. Gilteritinib was associated with improved EFS compared with midostaurin (HR 0.645, 95% CI 0.424–0.983; p=0.0318). Three-year EFS was 54.4% with gilteritinib compared with 38.1% with midostaurin. Median EFS was not reached with gilteritinib and was 13.4 months with midostaurin. In a sensitivity analysis censoring follow-up at HCT, median EFS was 18.0 months with gilteritinib and 9.4 months with midostaurin (HR 0.638, 95% CI 0.395–1.032; p=0.0506). Sixty-four deaths had occurred (30 with gilteritinib, 34 with midostaurin). Median OS was not reached in either treatment arm (HR 0.711, 95% CI 0.430–1.175; p=0.181). In the analysis censoring at HCT, median OS was 44.1 months with gilteritinib and 26.9 months with midostaurin (p=0.309).
Conclusions
Although the PrE0905 primary endpoint of post-induction FLT3 mutation-negative CRc was not met, gilteritinib combined with intensive chemotherapy resulted in higher CRc rates, increased rates of HCT in first remission, and now, improved EFS compared with midostaurin. The EFS benefit was maintained in analyses censoring at HCT. OS analysis favors gilteritinib (HR 0.711); however, with only 64 death events and median OS not reached in either treatment arm the study remains underpowered to definitely assess an overall survival benefit . With 19.7% gilteritinib vs 31.7% midostaurin treated patients relapsing, this analysis provides evidence from a randomized trial of an event-free survival benefit of gilteritinib, a second-generation FLT3 inhibitor, compared with midostaurin when combined with chemotherapy in newly diagnosed FLT3-mutated AML.
DISCLOSURES
Selina Luger, MD, FRCPC: Astra Zeneca - Consultancy (Includes expert testimony); Quetzal - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony)